Lupin Receives U.S. FDA Approval For Modafinil Tablets

Market snapshot: Lupin Limited has secured US FDA approval for Modafinil tablets, indicated to improve wakefulness in adult patients with sleep disorders. The approved drug is bioequivalent to Nuvo Pharmaceuticals' Provigil, targeting an estimated US market size of USD 70.7 million. This regulatory approval adds depth to Lupin's growing US portfolio, which drove strong results in the latest quarter.

Data Snapshot

• Estimated US annual market size for Modafinil tablets is USD 70.7 million
• Lupin consolidated PAT for Q1 FY27 rose 16% YoY to ₹1,416.98 crore
• US market sales grew 42.9% YoY to ₹3,434.8 crore in Q1 FY27

What's Changed

• U.S. FDA approval for Modafinil Tablets expands Lupin's central nervous system generic portfolio in North America.
• Lupin's Q1 FY27 net profit rose 16% YoY to ₹1,416.98 crore, up from ₹1,221.46 crore, driven by robust performance across key markets.
• US sales reached ₹3,434.8 crore in Q1 FY27, up 42.9% YoY from ₹2,404.1 crore, solidifying North America as a primary growth driver.

Key Takeaways

• Lupin's Modafinil tablets received final US FDA approval as a bioequivalent to reference listed drug Provigil.
• The approved formulation targets excessive sleepiness associated with narcolepsy, obstructive sleep apnea, and shift work disorder.
• The market opportunity for Modafinil tablets in the United States is estimated at USD 70.7 million annually.
• This approval aligns with Lupin's focus on expanding complex generics and CNS therapies in its high-growth US market.

SAHI Perspective

The US FDA approval of Modafinil tablets represents another incremental win for Lupin's North American business, which remains its biggest revenue contributor. By targeting a USD 70.7 million generic market with a bioequivalent version of Provigil, Lupin continues to leverage its robust global manufacturing network to drive steady volume gains. This consistent cadence of approvals helps offset ongoing base-portfolio price erosion and supports long-term operating margins.

Market Implications

The news is positive for Lupin's stock as it demonstrates execution on its ANDA pipeline. It reinforces market confidence in Lupin's ability to navigate US FDA regulatory pathways and steadily commercialize new products. Improved CNS portfolio depth is likely to support North American sales momentum, which grew 42.9% YoY in Q1 FY27.

Trading Signals

Market Bias: Bullish

Lupin's US FDA approval of Modafinil tablets strengthens its CNS portfolio in a USD 70.7 million market. This comes on the heels of robust Q1 FY27 performance where US sales grew 42.9% YoY to ₹3,434.8 crore, reinforcing strong structural momentum.

Overweight: Healthcare, Pharmaceuticals

Trigger Factors:

• US launch timeline and pricing strategy of Modafinil tablets.
• Competitive generic entrants in the Modafinil product category.
• Pricing trends of high-margin products like generic Tolvaptan in the US.

Time Horizon: Near-term (0-3 months)

Industry Context

Indian pharmaceutical companies are increasingly focusing on niche formulations and complex generics to counter high pricing pressure in the US generic market. CNS therapies, sleep disorder treatments, and interchangeable biosimilars represent lucrative spaces with relatively lower competition compared to simple oral solids. Lupin's focus on building a differentiated US portfolio has been a key factor in its recent margin expansion, with consolidated EBITDA margins reaching 24.7% in FY25.

Key Risks to Watch

• Potential delays in the commercial launch and supply chain execution for Modafinil tablets in the US market.
• Intensity of generic competition from other pharmaceutical majors already operating in the Modafinil space.
• Any future regulatory inspection findings at Lupin's global manufacturing sites.

Recent Developments

On August 20, 2026, Lupin's subsidiary VISUfarma B.V. entered into an exclusive licensing agreement with Visus Therapeutics Inc. to commercialize YUVEZZI™ for the treatment of presbyopia in adults across Europe, the UK, Switzerland, Norway, and Iceland. Additionally, Lupin reported a 16% YoY increase in Q1 FY27 consolidated PAT to ₹1,416.98 crore, supported by strong US sales of ₹3,434.8 crore.

Closing Insight

Lupin's steady stream of US FDA approvals, paired with strategic European licensing deals, underscores its dual-track growth strategy of complex generic expansion and specialty portfolio scaling, positioning the company well for resilient earnings growth.

High Performance Trading with SAHI.